PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF CREATININE-DRUG INTERACTION IN CHRONIC KIDNEY DISEASE POPULATION.

被引：0
|
作者：
Takita, H. [1 ,2 ]
Scotcher, D. [1 ]
Chinnadurai, R. [3 ]
Kalra, P. [3 ]
Galetin, A. [1 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Asahi Kasei Pharma, Shizuoka, Japan
[3] Salford Royal NHS Fdn Trust, Salford, Lancs, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-130
引用
收藏
页码：S113 / S114
页数：2
相关论文
共 50 条
  • [41] Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach
    Pan, Chunyang
    Cheng, Yifan
    He, Qingfen
    Li, Min
    Bu, Fengjiao
    Zhu, Xiao
    Li, Xiaoyu
    Xiang, Xiaoqiang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 373
  • [42] Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach
    Schaller, Stephan
    Martins, Frederico S.
    Balazki, Pavel
    Bohm, Sonja
    Baumgart, Joachim
    Hilger, Ralf A.
    Beelen, Dietrich W.
    Hemmelmann, Claudia
    Ring, Arne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1722 - 1734
  • [43] Physiologically-based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co-administered with ritonavir
    Sun, Zexu
    Zhao, Nan
    Xie, Ran
    Jia, Bo
    Xu, Junyu
    Luo, Lin
    Zhuang, Yulei
    Peng, Yuyu
    Liu, Xinchang
    Zhang, Yingjun
    Zhao, Xia
    Liu, Zhaoqian
    Cui, Yimin
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (09): : 1503 - 1512
  • [44] Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A
    Zheng, Aole
    Yang, Dongsheng
    Pan, Chunyang
    He, Qingfeng
    Zhu, Xiao
    Xiang, Xiaoqiang
    Ji, Peiying
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 196
  • [45] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
    Duan, P.
    Zhao, P.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S16 - S17
  • [46] Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
    Jee Sun Min
    Soo Kyung Bae
    Archives of Pharmacal Research, 2017, 40 : 1356 - 1379
  • [47] Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling
    Samant, Tanay S.
    Huth, Felix
    Umehara, Kenichi
    Schiller, Hilmar
    Dhuria, Shyeilla, V
    Elmeliegy, Mohamed
    Miller, Michelle
    Chakraborty, Abhijit
    Heimbach, Tycho
    He, Handan
    Ji, Yan
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 575 - 585
  • [48] Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions
    Lewis, Gareth J.
    Ahire, Deepak
    Taskar, Kunal S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 563 - 575
  • [49] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUG-DRUG INTERACTION (DDI) BETWEEN TEMSIROLIMUS AND ITS METABOLITE SIROLIMUS WITH MIDAZOLAM.
    Lin, J.
    Loi, C. -M.
    Tse, S.
    Boni, J.
    Shetty, B. V.
    Goosen, T. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S37 - S37
  • [50] Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion
    K. Sandy Pang
    Matthew R. Durk
    Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37 : 591 - 615
12345